Development of a dendrimer PAMAMbased gold biochip for rapid and sensitive detection of endogenous IFNγ and antiIFNγ IgG in patients with hemophagocytic lymphohistiocytosis.
Mol Med Rep
; 22(6): 5369-5377, 2020 Dec.
Article
en En
| MEDLINE
| ID: mdl-33173980
ABSTRACT
Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe disease characterized by immune hyperactivation and cytokine storm. Given the high mortality rate of HLH, there is a need for more effective diagnostic tools and treatments. The present study developed a dendrimerbased protein biochip for rapid, sensitive and simultaneous detection of serum interferon (IFN)γ and endogenous antiIFNγ antibody (Ab) in patients with HLH. A gold biochip was modified with 1, 4phenylene diisothiocyanate (PDITC), polyamidoamine (PAMAM) or PDITCactivated PAMAM. The optimal immobilization concentration for Ab capture and the reaction concentration for detecting Ab on the PDITCactivated PAMAMmodified biochip were 6.25 and 3.12 µg/ml, respectively; the limit of detection of IFNγ protein was 50 pg/ml. The efficiency of the proteinprobed biochip in detecting IFNγ and antiIFNγ Ab in serum samples from 77 patients with HLH was evaluated; the positive rates for IFNγ and antiIFNγ IgG Ab were 63.6% (49/77) and 61.0% (47/77), respectively. The present results demonstrated that the PDITCactivated PAMAMmodified biochip might be a sensitive tool for the specific detection of IFNγ and antiIFNγ Ab in serum, and might have clinical applicability for the diagnosis of HLH.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Análisis por Matrices de Proteínas
/
Linfohistiocitosis Hemofagocítica
/
Dendrímeros
Tipo de estudio:
Diagnostic_studies
Límite:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
/
Middle aged
/
Newborn
País/Región como asunto:
Asia
Idioma:
En
Revista:
Mol Med Rep
Año:
2020
Tipo del documento:
Article
País de afiliación:
Alemania